RPh201: Clinical Trials

3 trials of RPh201, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Withdrawn 1
Phase 11Withdrawn 1

Follow RPh201: new trials by email Literature Review of RPh201 trials Research Report on RPh201

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
RPh201, Placebo - Mild to Moderate Dementia Due to Alzheimer's Disease, With or Without Coexisting Cerebrovascular Disease
Phase 2CompletedRegenera Pharma Ltd832018-03-012020-04-30
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
RPh201, Placebo - Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries
Phase 2CompletedRegenera Pharma Ltd222014-02-012020-03-19
The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements
RPh201, saline - Chronic Vegetative State
Phase 1 / Phase 2WithdrawnHadassah Medical Organization2011-10-012015-09-22

Conditions studied

Alzheimer Disease (1)  ·  Dementia (1)  ·  Optic Nerve Injuries (1)  ·  Optic Neuropathy, Ischemic (1)  ·  Persistent Vegetative State (1)

Sponsors

Regenera Pharma Ltd (2)  ·  Hadassah Medical Organization (1)

Countries

Canada (1)  ·  Israel (1)

Top investigators

Sharon Cohen, MD (1)  ·  Tamir Ben-Hur, MD PhD (1)  ·  Zvi Segal,, MD (1)